Cell-Free DNA as a Novel Marker in Cancer Therapy
Authors:
- 15 July 2015
- journal article
- Published by Taylor & Francis in Biomarkers in Medicine
- Vol. 9 (7) , 703-712
Abstract
Advances in next-generation sequencing have provided new insights and new therapeutic options for patients with cancer. However, assessment of genomic aberrations, which is required for precision medicine, has been challenging because of the difficulties in capturing intratumoral heterogeneity and in real-time assessment of tumors. Recent advances in technology have enabled detection and analysis of cell-free DNA in cancer patients, which provides real-time assessment of tumor evolution. Here, we review the recent advances in our understanding of the clinical utility of cell-free DNA and the future directions for its use in cancer management.Keywords
Funding Information
- Elsa U Pardee Foundation, the Sidney Kimmel Foundation for Cancer Research
- the Sheikh Khalifa Al Nahyan Ben Zayed Institute
- the National Center for Advancing Translational Sciences (UL1 TR000371)
- National Institutes of Health through MD Anderson’s Cancer Center ((P30 CA016672))
- Novartis, BioMed Valley Discoveries, Astellas,
- Foundation Medicine, Biocartis, Trovagene and Transgenomic
This publication has 56 references indexed in Scilit:
- A Decision Support Framework for Genomically Informed Investigational Cancer TherapyJNCI: Journal of the National Cancer Institute, 2015
- Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer EvolutionCancer Cell, 2015
- Concordance of Genomic Alterations between Primary and Recurrent Breast CancerMolecular Cancer Therapeutics, 2014
- Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR InhibitorsCell Reports, 2014
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialThe Lancet, 2012
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR InhibitorsScience Translational Medicine, 2011
- PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast CancerClinical Cancer Research, 2011
- Understanding resistance to EGFR inhibitors—impact on future treatment strategiesNature Reviews Clinical Oncology, 2010
- Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal bloodProceedings of the National Academy of Sciences of the United States of America, 2008
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005